AGC
DNA icon

Aspen Grove Capital’s Ginkgo Bioworks DNA Stock Holding History

Aspen Grove Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,000
Closed -$53.5K – 211
2024
Q2 		$53.5K Buy
4,000
+250
+7% +$7.46K 0.01% 204
2024
Q1 		$174K Buy
3,750
+750
+25% +$38.8K 0.05% 198
2023
Q4 		$161K Buy
3,000
+2,500
+500% +$153K 0.05% 181
2023
Q3 		$36.2K Hold
500
– – 0.01% 171
2023
Q2 		$37.2K Hold
500
– – 0.01% 194
2023
Q1 		$26.6K Buy
+500
New +$31.7K 0.01% 151

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aspen Grove Capital's DNA Position: Q3 2024 in Review

Aspen Grove Capital sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 4,000 shares — an estimated $53.5K sold.

Aspen Grove Capital first reported a position in DNA in Q1 2023 and held it in 6 quarters. The position peaked at $174K in Q1 2024. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Aspen Grove Capital reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Aspen Grove Capital sold 4,000 Ginkgo Bioworks shares in Q3 2024, an estimated $53.5K.
  • Aspen Grove Capital first reported a position in Ginkgo Bioworks in Q1 2023 and held it in 6 quarters.
  • Aspen Grove Capital's Ginkgo Bioworks position peaked at $174K in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Aspen Grove Capital's 13F filing for Q3 2024, filed 13 Nov 2024.